Global call for action on drug-resistant infections, 12-13 October 2017, Berlin
Conference organized by Wellcome Trust in partnership with the UK, Ghanaian and Thai governments and the UN Foundation
The Innovative Medicines Initiative (IMI) is the world’s biggest public-private partnership in life sciences between the EU (represented by the European Commission) and the biopharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations), who jointly fund public private consortia working together to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need, and limited market incentives, such as antimicrobial resistance (AMR).
IMI is at the forefront of R&D into AMR. IMI’s New Drugs 4 Bad Bugs (ND4BB) program represents an unprecedented partnership (with to date more than 750 mln EUR public and private investment) between industry, academia and biotech organizations to combat AMR in Europe by tackling the scientific, regulatory, and business challenges that are hampering the development of new antibiotics. In addition, IMI works to improve the efficacy of vaccines and on the role of diagnostics in preventing AMR.
Looking to the future, the industry is committed to further supporting AMR-related initiatives in IMI, with particular focus on enhancing overall industry/SME/Academia success in AMR discovery and development through establishment of incubators and accelerators, as well as clinical trials network to create expert and sustained capability for AMR related trials in Europe and thereby creating a significant push incentive for investing into AMR.
+41 22 338 32 08
+32 2 626 25 55